**2024 European guidelines for the management of genital herpes**

**Authors**:

Rajul Patel1,2, Benjamin Moran 3, Emily Clarke4,5, Anna Geretti6,7 ,8, Stephan Lautenschlager9, John Green10, Gilbert Donders11, Mikhail Gomberg12, George Sorin13, 14 and Elizabeth Foley1

1. Department of Genitourinary Medicine, Southampton, UK
2. Southampton Medical School, Southampton, UK
3. Croydon University Hospital, Croydon Health Services Trust, London, UK
4. Axess Sexual Health, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
5. University of Liverpool, Liverpool, UK
6. Fondazione PTV, University of Rome Tor Vegata, Rome, Italy
7. North Middlesex University Hospital, London, UK
8. King’s College London, London, UK
9. Dermatologisches Ambulatorium Triemli, Zurich, Switzerland
10. Central and North West London NHS Trust, London, UK
11. Department of Obstetrics and Gynecology, University Hospital Antwerp, Belgium
12. Chief Researcher at Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia
13. Head and Chair Dermatology 2, Colentina Clinical Hospital, Bucharest, Romania
14. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

**Abstract:**

Genital herpes is one of the commonest sexually transmitted infections worldwide. Using the best available evidence, this guideline recommends strategies for diagnosis, management, and follow-up of the condition as well as for minimising transmission. Early recognition and initiation of therapy is key and may reduce the duration of illness or avoid hospitalisation with complications, including urinary retention, meningism or severe systemic illness. The guideline covers a range of common clinical scenarios, such as recurrent genital herpes, infection during pregnancy and coinfection with human immunodeficiency virus.

**Declarations of interest**:

None of the authors or editors had any conflicts of interest for the content of this guideline.

**Keywords:**

Herpes simplex, HSV, genital herpes, Europe, treatment

**Revision date: 2029**

**Principle changes made to the European guidelines for the management of genital herpes.**

* The need for and importance of considering a wider range of pathogens when assessing a case of genital ulceration.
* The importance of excluding HSV in infectious proctitis
* Clearer recommendations around interpretation of type specific serology.
* Recommended regimens for suppressive therapy, including recommendations for second stage treatment for poorly controlled patients.
* Advice on investigations in those poorly controlled on suppressive therapy.
* Clarification of duration of course of treatment for an initial episode of HSV
* Advice on timing the start of antivirals in pregnancy (pre-third trimester disease) based on local epidemiology of preterm delivery and neonatal herpes infection.

**INTRODUCTION**

First infection with either herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) is termed primary infection and results in either symptomatic disease at the site of viral entry (i.e., on the face or genital area) or asymptomatic, and thus unrecognised, infection. In addition, there may be systemic symptoms, as with other acute viral illnesses. Only a third of patients who acquire genital herpes have any recognised clinical features at the time of acquisition. Following infection, the virus becomes latent in the local sensory ganglion, periodically reactivating to cause symptomatic lesions, or undergo asymptomatic, but nonetheless infectious, viral shedding. Genital herpes can be caused by either HSV-1 – the usual cause of oro-labial herpes – or by HSV-2. Infection with either virus can cause an identical initial illness; however, the actual clinical presentation may depend upon previous HSV-1 or HSV-2 infection, and previous sites of infection. Subsequent recurrence frequency is greater for HSV-2 than HSV-1 disease when infection involves the genital area.

**Transmission risk**

Risk of transmission appears to be greatest during lesional recurrences or prodrome, and patients should be advised to abstain from sexual contact during this time. Transmission can occur in the absence of lesional recurrence as a result of sub-clinical viral shedding. Efficacy of condoms to prevent sexual transmission has not been formally assessed; however, indirect evidence from failed vaccine trials provides strong support for their consistent usage to prevent transmission to both males and females (1, B).1,2 The efficacy of condoms is easier to demonstrate in male to female transmissions where increasing consistent use results in lower levels of transmission.

**DIAGNOSIS**

**Clinical diagnosis**

Although classical genital herpes can be recognised by the presence of typical papular lesions progressing to vesicle and ulcer formation, associated with local adenitis and in recurrent cases preceded by prodromal symptoms, the features in many patients can be highly variable. The majority of patients will suffer from atypical lesions where signs may be easily confused with other genital dermatoses. In all cases, but in particular for atypical cases, depending upon clinical diagnosis alone should be avoided.

Herpes is an important cause of proctitis and should be considered in those where a sexually transmitted pathogen is being considered.

**Differential diagnosis**

The differential diagnosis of genital ulceration is wide but in the context of young sexually active populations in Europe presenting with painful blistering eruptions an infective cause is usually likely. Care must be taken to ensure that the possibility of mixed infections is considered. Syphilis is increasing in frequency and can cause painful lesions particularly in the perianal area. Herpes zoster is the cause of the genital blistering in 2% of cases (although mostly at the extremes of age) and sporadic cases of Mpox are reported in at risk populations despite vaccination.

The use of combined herpes simplex, syphilis and zoster PCR routinely for genital samples mitigates some of the risk of missing these infections.

**Laboratory diagnosis**

*Virus detection*

* Laboratory confirmation is recommended in all patients with suspected genital herpes, using methods that directly demonstrate the virus in genital specimens, typically swabs should be taken from the base of the lesion (vesicles should be unroofed with a needle or scalpel blade) (Ib, A).3 Viral detection in early disease (for both first episodes and recurrences) are much more likely to be successful. In suspected recurrent disease, patient taken swabs (at home) can be better at demonstrating virus then those taken in clinical settings. Viral production rapidly peaks during a herpes episode and swabbing for laboratory confirmation should not be delayed.
* HSV typing into HSV-1 and HSV-2 is recommended in all patients with first-episode genital herpes to guide counselling and management (1, C).1
* As HSV shedding is intermittent, testing swabs from asymptomatic patients is not recommended for routine diagnosis since it is unlikely to yield confirmation of carrier status (1, A).1
* HSV DNA detection is now considered the gold standard for diagnosis. Compared with cell culture it is both more sensitive and specific (1, A)3-8 and increases HSV detection rates in muco-cutaneous swabs by 11-71% and is recommended as the preferred diagnostic method (1, A).3,7,8 Real-time PCR can tolerate less stringent conditions for sample storage and transport than virus culture, and allows the rapid detection and typing of HSV with a lower risk of contamination than traditional PCR assays. Cell culture may occasionally be required to determine anti-viral sensitivity, but it is increasingly unavailable to clinicians.
* Viral antigen detection methods such as direct immunofluorescence assay (IFA), enzyme immunoassay (EIA) and Tzanck and Papanicolaou staining are no longer recommended except in extremely limited resource settings (1, A).9-11

*HSV type-specific serology*

Serological testing is not routinely recommended in asymptomatic patients (1, D), but may be useful in the following groups:1,12-17

* History of recurrent or atypical genital disease when direct virus detection methods have been negative (1, C). HSV-2 antibodies are supportive of a diagnosis of genital herpes; HSV-1 antibodies do not differentiate between genital and oro-pharyngeal infection. Counselling of HSV-2 IgG negative, HSV-1 IgG positive patients should take into account that HSV-1 is an uncommon cause of recurrent genital disease.1
* First-episode genital herpes, where differentiating between primary and established infection guides counselling and management (1, C). At the onset of symptoms, the absence of HSV IgG against the virus type detected in the genital lesion is consistent with a primary infection.1 Seroconversion should be demonstrated at follow-up, typically at 90 days.
* Sexual partners of patients with genital herpes, where concerns are raised about transmission. Serodiscordant couples can be counselled about strategies to reduce the risk of infection and disease (1, A).
* Asymptomatic pregnant women should be routinely recommended to be tested if there is a history of genital herpes in the partner (1, B).18-20 HSV-1 and/or HSV-2 seronegative women should be counselled about strategies to prevent a new infection with either virus type during pregnancy.

Care must be taken in interpreting negative results since antibodies to both HSV-1 and 2 may not form or be lost with time.

Limited data suggest an increased risk of perinatal HIV transmission among HSV-2 seropositive HIV-infected women.21,22 As evidence is not consistent, testing of HIV positive pregnant women is not routinely recommended (1, D).23

HSV serological assays that detect antibodies against the antigenically unique glycoproteins gG1 and gG2 should be used.11,24 Non type-specific HSV antibody assays are of no value in the management of genital herpes.

Western blot (WB) is the diagnostic gold-standard. It is >97% sensitive and >98% specific but is labour-intensive and not commercially available.25,26

The sensitivities and specificities of commercially available seroassays can vary significantly across populations.27-36 The positive predictive value (PPV) in low prevalence settings can make results uninterpretable. False negative results are more likely to occur in early infection and can be resolved by repeat testing.

HSV seroprevalence rates, the presence of risk factors for genital herpes, and clinical history influence the positive predictive value (PPV) of HSV type-specific serology and should guide testing and result interpretation (1, C).13,22-31 The specificities of ELISA tests can be improved by raising the index value for interpreting positivity and testing all intermediate specimens with an alternate confirmatory test (1, B).26,27,29-31

IgM testing is not recommended in routine clinical practice. Studies suggest that 12-30% of patients lose their HSV type specific IgG antibodies depending on their HSV types and the test used.37

**MANAGEMENT**

**First-episode genital herpes**

*Indications for therapy*

First episodes of genital herpes are frequently associated with a prolonged disease course. Untreated, many patients suffer general and local complications. Therapy can be highly effective and should be instigated at the earliest opportunity and on clinical suspicion alone.

*Antivirals*

Patients presenting within 5 days of the start of the episode, or while new lesions are still forming, should be given oral antiviral drugs. Aciclovir, valaciclovir and famciclovir are all effective in reducing the severity and duration of episode (1, A).38,39 No therapy alters the natural course of genital herpes infection.

Topical agents are not recommended as they are less effective than oral agents and easily generate resistance (1, D).40

The only indication for the use of intravenous therapy is when the patient is unable to swallow or tolerate oral medication because of vomiting. The recommended regimens – all for five to ten days – are:

* Aciclovir 400 mg three times a day, or
* Aciclovir 200 mg five times a day, or
* Famciclovir 250 mg three times a day, or
* Valaciclovir 500 mg two times a day

Choice should be made by individual clinicians, taking cost of therapy and likely compliance into account. A number of patients will have extended episodes beyond five days. If a decision to provide five days of therapy is made, the patient should have early review to ensure they have no further lesion development, systemic symptoms or disease complications – they all will require extended therapy. It will often be expedient to provide at least a seven-day course of treatment to ensure the patient does not run out of therapy at a weekend.

*Supportive measures*

Bathing with normal saline and the use of appropriate analgesia are recommended. Although the potential for sensitisation exists in the use of topical anaesthetic agents, lidocaine is a rare sensitizer and can be used safely in genital herpes in the form of gel or ointment.41 Benzocaine, however, is a potent sensitizer and should not be used (1, D). In women with severe dysuria, urination with the genitals submerged in water or physiological saline solution along with spreading the labia can alleviate symptoms.

*Counselling*

It is important to be frank about transmission risks including subclinical shedding and the limited impact of condoms and antivirals. Advice on disclosure should be practical and tailored to the patient’s personal situation. The low physical morbidity and high population prevalence should be stressed. Clear information about pregnancy is important both to men and women. High distress at diagnosis is common, often persists with recurrences and may be reduced by antivirals (1, A).42-44 Most patients require one or two sessions but adjustment is difficult to predict and careful follow up is important with more intensive input for those who do not adjust within 3-6 months.

*Management of complications*

Hospitalisation may be required for urinary retention, meningism, severe constitutional symptoms, or adverse social circumstances. If catheterisation is required, consideration should be given as to whether a suprapubic approach offers better symptom control to the individual patient. Super infection of lesions is rare but may occur during the second week. This is characterised by the recrudescence of local symptoms. Candida is most often implicated and is easily diagnosed and treated.

Genital HSV can theoretically be associated with superinfection of atopic dermatitis, relapsing eczema herpeticum, or be associated with recurrent erythema multiformae. Occasional case reports are described, and the management is identical to that for these complications when arising from oral HSV-1.

*Special situations – patients living with HIV with first-episode genital herpes.*

There are no controlled trials on duration and dose of treatment. Some clinicians advocate a 10-day course of treatment at twice the standard dose of any of the usual agents (1, D).

*Acquisitions in the third trimester of pregnancy*

Late pregnancy acquisitions are associated with high risks of transmission and morbidity in the neonate. Acyclovir and Valaciclovir at standard doses are recommended but should be continued to term (when delivery by Caesarean Section is advisable).

**Information for patients**

The following information should be discussed when counselling patients with first episode genital herpes:

* The course of infection, including subclinical shedding
* Treatment options
* The risk of transmission, and interventions that may limit or reduce the risk of transmission.
* The risk of transmission to the infant at birth. The patient should be counselled to inform the obstetrician or midwife.
* The possibility of partner notification and the possible source of infection
* That transmissions can occur from an asymptomatic partner some years into a monogamous relationship.

**Follow-up**

Patients are followed-up until the episode has resolved and counselling is considered complete. Further follow-up may be required to exclude other causes of genital ulceration that may be co-existent. Patients should be invited to re-attend should recurrences be problematic.

**Recurrent genital herpes**

*Indications for therapy*

Genital herpes recurrences are self-limiting and generally cause minor symptoms. The level of distress, and the disruption caused to individual’s sexual and social life is often independent of the frequency of symptoms. Decisions about how best to manage clinical recurrences should be made in partnership with the patient. Management strategies include supportive therapy only, episodic antiviral treatments, and suppressive antiviral therapy. The most appropriate strategy for managing an individual patient may vary over time according to recurrence frequency, symptom severity, and relationship status. For most patients, management will need to be supportive only, with simple local measures such as saline bathing or topical petroleum jelly being adequate.

*Episodic antiviral treatment*

Oral aciclovir, valaciclovir and famciclovir are effective at reducing the duration and severity of recurrent genital herpes. The reduction in duration is a median of 1-2 days (1, A).45-47 Head-to-head studies of their effects show no advantage of one therapy over another, or the advantage of extended 5-day treatment over ultra-short therapy. Prodrugs offer simplified twice-a-day dosing. Patient-initiated treatment started within 24 hours is most likely to be effective. Aborted lesions have been documented in up to one third of patients with early treatment.48 To ensure prompt treatment, patients should be advised to carry a small quantity of drugs at all times and not rely on sourcing medication after a recurrence starts.

Short course therapies should be tried in the first instance:

* Aciclovir 800 mg three times daily for 2 days, or49
* Famciclovir 1 gram twice daily for one day, or50
* Valaciclovir 500 mg twice daily for 3 days (1, A).49,51-54

Alternative longer 5 day courses include :

* Aciclovir 400 mg three times daily for 3-5 days, or
* Aciclovir 200 mg five times daily, or
* Valaciclovir 500 mg twice daily or
* Famciclovir 125 mg twice daily.

*Suppressive therapy*

The majority of early trials of suppressive therapy were done in patients with a recurrence rate equivalent to ≥6 recurrences/annum. More recently, studies have been completed in patients with much milder disease. These indicate that patients across all spectrums of disease will benefit from a reduced rate of recurrence with treatment. The frequency of recurrence at which it is worth starting suppressive therapy is a subjective issue and needs to balance the frequency of recurrence, the impact of disease on the individual and the need to manage transmission risk against the cost and inconvenience of treatment.

All patients are highly likely to experience a substantial reduction in recurrence frequency on suppressive antiviral therapy. However, the majority of patients on such a regimen will still experience an occasional symptomatic recurrence.

Experience with suppressive antiviral therapy is most extensive with aciclovir (1, A).55 Safety and resistance data on patients on long-term therapy now extends to over 18 years of continuous surveillance. There is no accumulative toxicity or organ damage in long term use. Dose adjustments are only required in severe renal disease. Regular blood monitoring in otherwise well patients is not recommended. Although not essential, it may be prudent to regularly assess the need for continuing therapy, since patient circumstances may alter significantly. However, even after prolonged periods of suppression, many patients do not find a significant alteration in disease frequency or severity upon discontinuation and reassessment.

A few patients continue to experience frequent virologically confirmed symptomatic recurrences despite full dose antiviral therapy. Outside the immunocompromised population this is very unlikely to be due to resistant herpes simplex virus. Investigations hoping to find a treatable immunological cause in these patients are not useful and, other than excluding HIV, no further investigations are warranted. Therapy involving interferon to improve control cannot be recommended, since these have not been widely assessed and are only available in parts of Eastern Europe.

*Recommended regimens*

The optimal total daily dose of suppressive aciclovir therapy is 800 mg. The only published clinical dose-ranging study concluded that 200 mg 4 times a day was marginally superior to 400 mg twice daily (p<0.02) (1, B).56 However, ability to adhere with a 4 times a day dosing regimen should determine prescribing decisions for individual patients. Twice-daily valaciclovir (250 mg twice daily) has been shown to be as effective as twice-daily aciclovir (400 mg twice daily). Once daily aciclovir does not suppress genital herpes recurrences. There is some debate as to whether once daily therapy is as effective as twice daily therapy with valaciclovir. For those patients experiencing <10 recurrences per annum, a dose of 500 mg once daily valaciclovir will be adequate; for those patients experiencing >10 recurrences per annum, 250 mg twice a day or 1 g once a day is required.57

No major clinically significant differences between suppressive therapy with valaciclovir (500 mg daily) and famciclovir (250 mg twice daily) have been documented (1, D).8 In patients with an insufficient clinical response the daily suppressive dose of valaciclovir or famciclovir may have to be doubled (1, D). Routine blood monitoring of standard dose therapy is not required. Occasionally a mild headache or nausea may occur with valaciclovir.

The decision to continue suppressive therapy should be reviewed at least annually. Discontinuation of therapy at this time, if the patient is willing, will allow a reassessment of recurrence frequency. A small number of patients will experience a reduction in recurrence frequency compared with pre-suppression symptomatic levels. The minimum period of assessment should include two recurrences to allow a view to be taken both on the frequency and severity. It is safe and reasonable to restart treatment in patients who continue to have significant disease (1, D).

Short courses of suppressive therapy to prevent clinical symptoms may be helpful for some patients (e.g. for holidays, exams, etc.). Clinicians need to note that full suppressive effect is usually only obtained five days into treatment.

Recommended doses:

* Aciclovir 400mg twice daily (for all frequencies of disease recurrence)
* Valaciclovir 500mg daily (if fewer than 10 recurrences per annum)
* Valaciclovir 1g daily (if more than 10 recurrences per annum)

Second stage therapy for poorly controlled patients:

* Aciclovir 400mg three times a day
* Valaciclovir 250mg twice a day
* Valaciclovir 500mg twice a day
* Aciclovir 200mg four times a day

*Viral shedding and transmission on suppressive therapy*

Subclinical shedding of infectious virus occurs in most individuals with genital HSV-1 and/or HSV-2. This virus is viable and is transmissible. Viral shedding is more likely to occur in patients with genital HSV-2, in the first year after infection, or in individuals with frequent symptomatic recurrences. Aciclovir, valaciclovir and famciclovir all suppress symptomatic and asymptomatic viral shedding.

Even if it seems biologically plausible, partial suppression of viral shedding does not necessarily equate to reduced transmission. However, suppressive therapy with valaciclovir 500 mg once a day (in those with 10 or fewer recurrent episodes per year) significantly reduced transmission – by nearly 50% - in serodiscordant couples (1, A).16 Twice daily aciclovir 400mg achieves similar levels of reduction in asymptomatic shedding to once daily VACV. Suppressive antiviral therapy may be considered in addition to the use of condoms and selective sexual abstinence when transmission concerns are present.

**SPECIAL SITUATIONS**

**Management of HSV in people with immunocompromise and in those living with HIV**

There is epidemiological synergy between Herpes simplex virus (HSV) and HIV infections.58,59 Herpes simplex infections activate HIV replicationand may facilitate onward HIV transmission to sexual partners.60-67 Suppressive treatment of HSV-2 infection with valaciclovir has been shown to reduce genital HIV shedding in women (not on ARVs).68 In addition, both prevalent and incident HSV-2 infections are associated with an increased risk of HIV acquisition.69,70

The natural history of genital herpes in untreated people living with HIV is significantly different from that in HIV-negative individuals. The most important risk factor for herpes reactivation is the degree of HIV associated immunosuppression.71-73

Standard systemic antiviral drugs, as used to treat genital herpes in HIV-negative patients, have been shown to successfully treat genital herpes in people living with HIV.74-79 Resistance to anti-herpes drugs is more common in those with HIV co-infection and is associated with treatment failure of genital herpes.80 Suppressive antiviral therapy with currently available agents has been shown in multiple studies to have no impact on HIV acquisition or transmission risk. HSV treatment used only to manage or reduce HIV transmission or acquisition risk cannot be recommended (1, A).81,82

Much of the evidence on herpes management in people living with HIV comes from studies performed before the era of combination antiretroviral therapy; prospective studies performed early in the epidemic showed that clinical lesions might be persistent and progressive in those living with HIV. Genital herpes, including chronic erosive lesions may occur as a manifestation of the immune reconstitution inflammatory syndrome (IRIS) following antiretroviral therapy.83-87 HSV associated IRIS may be unresponsive to previously effective anti-herpes viral therapy in the absence of increased antiviral resistance. Management is difficult but topical cidofovir may be effective.88

*Management of initial episode HSV*

There is no trial data for any antiviral in initial episode genital HSV in people living with HIV. The vast majority of adults living with HIV have serological evidence of established HSV-1 and -2 infections making acquisition trials extremely difficult to perform.

Case studies report that acquisition of genital HSV may be associated with a prolonged and uncertain clinical course. Systemic symptoms may predominate, and chronic lesions may become established if immunological clearance of the skin does not occur. In the absence of HIV therapy, primary genital herpes may be severe and prolonged with risk of progressive, multifocal, and coalescing mucocutaneous anogenital lesions. Moreover, serious, and potentially life-threatening systemic complications such as fulminant hepatitis, pneumonia, neurological disease and disseminated infection, have been reported.

In the absence of data most authorities advise that multiples of the standard levels of treatment for first episode HSV be used in the immunocompromised. However, for those living with HIV these may not always be required particularly for those with normal CD4 counts.

In patients living with advanced HIV, double the standard dose of antiviral should be considered and if new lesions continue to form at day 3-5 a higher dose should be considered. Prompt initiation of therapy is recommended. If new lesions are still forming after 3-5 days, a repeat viral isolation should be attempted, and susceptibility testing arranged (if possible). The dose of HSV therapy should also be increased.

Recommended initial doses in all people living with HIV :89

* Aciclovir 400mg five times daily, for 7-10 days (1, D)
* Valaciclovir 500-1g twice daily, for 10 days (1, D)
* Famciclovir 250-500mg three times daily, for 10 days (1, D)

Treatment should be given for at least 10 days or until all lesions have re-epithelialized – this will often exceed the usual 10 day duration of treatment that is given to HIV negative patients.

If fulminant disease ensues, then intravenous aciclovir be substituted at 5-10mg/kg body weight every 8 hours, for 2-7 days or until clinical improvement, and followed by oral antiviral therapy to complete a minimum of 10 days total treatment (1, D).

*Management of recurrent disease*

Both clinical and subclinical reactivations of genital herpes are more frequent in people living with HIV and may lead to persistent and progressive anogenital mucocutaneous lesions, especially with CD4 cell counts <50 per mm3. Features can be atypical in nature, and larger, deeper, and hypertrophic lesions can occur. Optimising the control of HIV replication with antiretroviral therapy is of fundamental importance for the management of recurrent genital herpes. Antiretroviral therapy will reduce the frequency of clinical recurrences but has less effect upon asymptomatic viral shedding. Thereafter, specific antiviral drugs can be used for either episodic or suppressive treatment. A number of trials of antiviral therapy in the immunocompromised have been reported.

*Episodic therapy*

It is likely that 5 days of therapy will be adequate for most patients. It should be noted that with advanced HIV 13-17% of patients have been reported to have new lesions developing at the end of a seven-day course of treatment. Shorter courses of therapy may be adequate in those with good CD4 counts (>500 cell/mm3) although only one trial with famciclovir has reported this effect (1, A).50

Standard doses of antivirals should suffice in those with no evidence of immune failure (1, A). In those living with advanced HIV, it may be necessary to double the standard doses and to continue therapy beyond 5 days (1, A). Caution should be exercised in using ultrashort courses of episodic therapy since these have not been evaluated fully in the immunocompromised.

*Suppressive therapy*

Suppressive antiviral therapy for HSV appears to be less effective in people living with HIV than in HIV negative people but remains well tolerated. All three agents have been trialled. Standard suppressive doses of aciclovir are effective. Valaciclovir is more effective when given twice daily (500mg bid) compared to once daily dosing (1000mg). The valaciclovir 500mg once daily dose has not been evaluated in those living with HIV. Trial data for the efficacy of high dose famciclovir is only available over much shorter durations.

It is recommended that intermittent cessation of suppressive antiviral therapy for genital herpes should occur, especially in those in whom there is also adequate inhibition of HIV replication and rising CD4 cell counts. In some people living with HIV with less frequent outbreaks of genital herpes, episodic treatment may be substituted. In others, where the pre-treatment pattern of recurrences resumes, suppressive treatment may need to restart (1, D).

There is a considerable body of data on the safety of oral antivirals in those living with HIV who are immunocompromised. Two studies in the pre-HAART era looked at high dose aciclovir (400mg four times a day) and more recently at standard dose regimens. For valaciclovir a number of studies looked at the value of valaciclovir for the suppression of recurrent genital herpes. High dose valaciclovir (2g four times a day) has been studied and reported in people living with HIV, and those immunosuppressed and recovering from bone marrow transplants. Most recently a large number of studies looking at the efficacy of aciclovir and valaciclovir suppression and its impact on HIV transmission from co-infected patients have been reported. These trials indicate that use of oral aciclovir at standard dose and valaciclovir at 1g od and 500mg twice a day is associated with little or no adverse effect or toxicity as compared with HIV negative people. High dose valaciclovir (8g daily) has been associated with Microangiopathic Haemolytic Uraemic syndrome.

Recommended drug regimens for daily suppressive treatment:89-91

* Aciclovir 400 mg orally twice to three times a day
* Valaciclovir 500 mg orally twice a day.

If these options do not adequately control disease, then the first option should be to double the dose. If control is still not achieved then famciclovir 500 mg orally twice a day can be tried (1, B).

*HSV suppression to limit HIV progression.*

Suppressive antiviral therapy with aciclovir or valaciclovir has been shown to decrease the levels of HIV viraemia in those patients with detectable HIV viral loads through a mechanism not yet fully elucidated.92 Such a strategy will impact on HIV progression, particularly for those individuals not on antiretroviral therapy. A large RCT in people with early HIV (those individuals not on antiretroviral therapy and with CD4 counts above 250 cells/mm3) has shown that standard doses of suppressive antiviral therapy (aciclovir 400mg twice a day) will sustain CD4 counts above 250 cell/mm3 and this effect reduced the need for antiretroviral at 2 years by 16% in the treatment group. However, benefits of suppressive antivirals have not been demonstrated in the presence of effective antiretroviral therapy.81,82 Effective antiretroviral therapy remains the priority for people living with HIV for their own health outcomes and to prevent transmission, and therefore HSV antiviral suppression to control HIV is unlikely to be clinically relevant in the vast majority of cases.

*Management of recalcitrant herpes in immunocompromised individuals.*

Although rare in immunocompetent individuals, clinically refractory lesions due to genital HSV are a major problem in patients with severe immunodeficiency, including late-stage HIV and patients with immune reconstitution inflammatory syndrome (IRIS) following antiretroviral therapy. Algorithms for treatment in such situations are shown in Figure 1. Systemic therapy with either foscarnet or cidofovir is generally preferred to treat drug resistant herpes in those living with HIV. There is evidence for alternating courses of treatment with aciclovir and cidofovir for subsequent recurrences as a strategy that may reduce the development of cidofovir-resistant strains. The efficacy, safety, and durability of the therapeutic response of these agents have yet to be determined in prospective controlled trials.

In prospective studies, aciclovir-resistant strains have been found in around 5-7% isolates from genital herpes lesions in people living with HIV.40,93,94 Aciclovir resistance is confirmed if isolates require aciclovir concentrations >1-3 mg/l for inhibition. Aciclovir resistance is most commonly related to a mutation in the gene encoding HSV thymidine kinase (TK), which is responsible for initial phosphorylation of aciclovir to its active form, resulting in TK that either has reduced affinity for aciclovir or is not synthesised. TK-deficient strains are of reduced pathogenicity in immunocompetent individuals but may cause serious local and systemic disease in severely immunocompromised individuals.95,96 They appear less likely to be associated with the development of latency; hence, subsequent clinical reactivations of genital herpes are often caused by aciclovir sensitive isolates. Partially resistant strains may sometimes be successfully treated with high dose intravenous aciclovir and other nucleoside analogues but fully aciclovir-resistant strains are resistant to valaciclovir and ganciclovir, and the majority are resistant to famciclovir.95-97 TK-deficient strains are susceptible to foscarnet and cidofovir which do not depend upon TK but which inhibit viral DNA polymerase.

Reports of outcomes in the open access pritilavir programme for immunocompromised people living with refractory lesions has shown great promise for this novel helicase primase inhibitor.

Antiviral susceptibility testing for HSV has limited availability and therefore the clinical response to antiviral therapy is often used to guide decisions, Advice from a clinical virologist about appropriate drug dosages and duration may be sought when clinical resistance is suspected.

**Figure 1**: Algorithm for the treatment of herpes in immunocompromised individuals.



\*All HSV strains resistant to aciclovir are also resistant to valaciclovir

\*\* These products will often have to be made up in house

Accessible lesions are those suitable for topical management.

**Management of partners**

There is no evidence on which to base recommendations for partner notification. On an individual basis, it may be appropriate to offer to see partners to help with the counselling process. Partner notification in relation to pregnancy is discussed below. It is worth considering the following points when counselling partners:

* The use of condoms is advisable especially when transmission concerns are present - even when the index case is on suppressive antiviral treatment.16
* Asymptomatic shedding plays a major role in the transmission of HSV infection and selective abstinence (abstinence during the presence of symptoms or signs) is therefore not an effective strategy for managing transmission risk.
* Partner notification is an effective way of detecting uninfected or asymptomatic individuals especially when combined with type-specific antibody testing.
* Up to 50% of asymptomatic HSV-2 seropositive women can be taught to recognise some of their genital herpes recurrences after counselling.98
* Virus transmission can be reduced either with suppressive antiviral treatment or by using condoms.

**Management of pregnant women with genital herpes**

***Management of pregnant women with first episode genital herpes***

*First and second trimester acquisition*

Management of the woman should be in line with her clinical condition and will often involve the use of either oral or intravenous aciclovir in standard doses.

Providing that delivery does not ensue, the pregnancy should be managed expectantly and vaginal delivery anticipated (1, D).

Daily suppressive aciclovir 400mg three times a day from 36 weeks gestation may prevent HSV lesions at term and hence the need for delivery by Caesarean section (1, A)99-104. In countries where the risk transmission is particularly high in premature neonates suppressive therapy should be started at an earlier time such as from 32 weeks gestation, and from 22 weeks in those identified as being at particularly high risk of premature delivery.

*Third trimester acquisition* (1, D)

Caesarean section should be considered for all women, particularly those developing symptoms within 6 weeks of delivery, as the risk of viral shedding in labour is very high (1, A).

Daily suppressive aciclovir 400mg three times a day to delivery should be considered.

If vaginal delivery is unavoidable, prolonged rupture of membranes and invasive procedures, including the use of scalp electrodes, should be avoided. Intrapartum IV aciclovir given to the mother and subsequently to the baby may be considered and the paediatrician should be informed.105

***Management of pregnant women with recurrent genital herpes* (1, C)**

Women with recurrent genital herpes should be informed that the risk of neonatal herpes is low.

*Management of recurrent HSV in late pregnancy*

Symptomatic recurrences of genital herpes during the third trimester will be brief; vaginal delivery is appropriate if no lesions are present at delivery.

For women with a history of recurrent genital herpes, the use of antiviral suppression has been demonstrated to reduce asymptomatic HSV shedding and lesions at term, and may also reduce premature delivery, but have not been studied sufficiently to definitively demonstrate prevention of neonatal HSV disease.100-109 Daily suppressive aciclovir 400mg three times a day from 36 weeks gestation should therefore be offered to all women with a history of genital herpes (1, A).110 This may be started earlier if there is any risk of prematurity such as from 32 weeks gestation, and from 22 weeks in those identified as being at particularly high risk of premature delivery.

If there are no genital lesions at delivery, there is no indication for a Caesarean section to prevent neonatal herpes.

Sequential PCR during late gestation to predict viral shedding at term is not indicated.111

The utility of taking PCR at delivery, in order to identify women who are asymptomatically shedding HSV, is unproven.

*Management of recurrent HSV in early pregnancy*

Although the safety of aciclovir in the 1st and 2nd trimester of pregnancy is not fully established, judicious use of this agent for suspected acquisition episodes is widely advocated. The same cannot be said for recurrent disease. Continuous or episodic therapy is not recommended in early pregnancy and should be avoided. Clinicians are on occasion obliged to use therapy for severe and complicated disease and a case-by-case assessment should be made. Famciclovir should not be used and the dose of aciclovir titrated down to the minimum effective level.

***Management of women living with HIV with recurrent HSV infection (1, D)***

There is some evidence that women living with HIV with genital HSV ulceration in pregnancy are more likely to transmit HIV infection independent of other factors.21,23 However, this is not a consistent finding across all studies.23

Women who are HIV antibody positive and have a history of genital herpes should be offered daily suppressive aciclovir 400mg three times a day from 32 weeks gestation to reduce the risk of transmission of HIV-1 infection especially in women where a vaginal delivery is planned. Starting therapy at an earlier gestation than usual should be considered in view of the increased possibility of preterm labour and consideration may be given to starting at 22 weeks of gestation in those at particularly high risk of premature delivery (1, D).

There is currently insufficient evidence to recommend daily suppressive treatment for HIV-1 antibody positive women who are HSV-1 or -2 seropositive but have no history of genital herpes.109,112.

***Management of women with genital lesions at onset of labour***

Caesarean section may be considered for women with recurrent genital herpes lesions at the onset of labour but the risk of neonatal herpes following vaginal delivery is small and must be set against risks to the mother of Caesarean section. Evidence from the Netherlands shows that a conservative approach, allowing vaginal delivery in the presence of a recurrent anogenital lesion, was not initially associated with a rise in numbers of neonatal HSV cases (1, C).113,114 However, this approach can only be adopted if fully supported by obstetricians and neonatologists, and if consistent with local medico-legal advice.

Clinical diagnosis of genital herpes at the time of labour correlates relatively poorly with HSV detection from genital sites by PCR and fails to identify women with asymptomatic HSV shedding.

**Note**: None of the antiviral drugs is licensed for use in pregnancy but the use of aciclovir in pregnancy has not been associated with any consistent pregnancy or foetal/neonatal adverse effects other than transient neutropenia.113,115 Safety data for aciclovir may be extrapolated to valaciclovir in late pregnancy, as it is the valine ester, but there is less experience with use of valaciclovir.106 Famciclovir should currently be avoided.116,117

***Prevention of acquisition of infection (1, D)***

Maternal risk of HSV acquisition in pregnancy varies geographically and local epidemiological surveillance should guide strategy for prevention. Any strategy for prevention of neonatal herpes needs to involve both parents.

All women should be asked at their first antenatal visit if they or their partner have had genital or oral herpes.

Female partners of men with genital herpes, but without a personal history of genital herpes should be advised about reducing their risk of acquiring herpes in pregnancy and of subsequent transmission to their baby. Strategies include selective and complete abstinence (especially in the third trimester) and conscientious condom use.

Daily suppressive treatment has been shown to significantly reduce the risk of transmission of HSV to a seronegative partner, however the effectiveness of suppressive treatment of the male partner to reduce transmission to a pregnant woman has not been evaluated so can currently only be recommended with caveats.

Pregnant women should be advised of the risk of acquiring HSV-1 as a result of receptive orogenital contact especially in the last trimester of pregnancy.

Identifying susceptible women by means of type-specific antibody testing has not been shown to be cost effective and is not indicated in Europe unless the history suggests they may be in a discordant relationship.

All women, not just those with a history of genital herpes, should undergo careful vulval inspection at the onset of labour to look for clinical signs of herpes infection.

Mothers, staff and other relatives/friends with active oral HSV lesions or herpetic whitlow should be advised to avoid direct contact between lesions and the neonate.

Table 1

|  |  |
| --- | --- |
| Strategies to prevent neonatal herpes in the serodiscorant couple: | |
| 1 | Complete abstinence from 26/40 of the pregnancy |
| 2 | Use of condoms for all sex acts irrespective of the absence of symptoms |
| 3 | Avoid sex with any symptoms or signs suggestive of genital herpes |
| 4 | Full dose suppression of the affected non pregnant partner |

***Management of the neonate***

*Babies born to mothers with first-episode genital herpes at the onset of labour*

The paediatrician should be informed.

HSV PCR from the oropharynx, nose, conjunctiva, rectum and any visible lesions, should be taken to allow early identification of infected babies. HSV PCR should be performed on a blood sample (it may take over 24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) and a lumbar puncture for CSF should be considered.

The potential benefits and risks of starting intravenous aciclovir without waiting for the results of these tests should be discussed.

If aciclovir is not started immediately the neonate should be closely monitored for signs of lethargy, fever, poor feeding, or lesions.

*Babies born to mothers with recurrent genital herpes at the onset of labour.*

Although some clinicians feel that taking a set of specimens for viral PCR collected 24-48hrs after delivery may help with early identification of infection there is no evidence to support this practice. However health care workers and parents should be advised to consider HSV in the differential diagnosis if the baby shows any signs of infection or develops skin, eye or mucous membrane lesions, particularly in the first two weeks of life or features of sepsis in the neonatal period.

Aciclovir Intolerance

Aciclovir intolerance is rare but is described. Minor allergic reactions to aciclovir or the excipients within tablets are difficult to distinguish but changing between the many generic brands often manages the problem. Urticarial reactions should be investigated and managed as per well-established, dermatological protocols. Neurotoxic reactions are rare and changing between Acyclovir and Valaciclovir will not be helpful.

**Proposed date for review:** 2029

A**cknowledgements:**

The authors wish to acknowledge the following individuals for their helpful comments:

**Composition of editorial board:**

Please refer to document at: <http://www.iusti.org/regions/Europe/pdf/2014/Editorial_Board2014.pdf>

**List of contributing organisations:**

Please refer to text at: http://www.iusti.org/regions/Europe/euroguidelines.htm

**References**

1. Casper C, Wald A. Condom use and the prevention of genital herpes acquisition. *Herpes*. Apr 2002;9(1):10-4.

2. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. *Ann Intern Med*. Nov 15 2005;143(10):707-13.

3. Gupta R, Warren T, Wald A. Genital herpes. *Lancet*. Dec 22 2007;370(9605):2127-37. doi:10.1016/s0140-6736(07)61908-4

4. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. *N Engl J Med*. Jun 4 1992;326(23):1533-9. doi:10.1056/nejm199206043262305

5. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. *J Infect Dis*. Nov 1 2003;188(9):1345-51. doi:10.1086/379043

6. Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. *Sex Transm Infect*. Oct 2004;80(5):406-10. doi:10.1136/sti.2003.008201

7. van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG. Diagnosing herpesvirus infections by real-time amplification and rapid culture. *J Clin Microbiol*. Feb 2003;41(2):576-80.

8. Geretti AM. Genital herpes. *Sex Transm Infect*. Dec 2006;82 Suppl 4:iv31-4. doi:10.1136/sti.2006.023200

9. Verano L, Michalski FJ. Herpes simplex virus antigen direct detection in standard virus transport medium by Du Pont Herpchek enzyme-linked immunosorbent assay. *J Clin Microbiol*. Nov 1990;28(11):2555-8.

10. Slomka MJ, Emery L, Munday PE, Moulsdale M, Brown DW. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. *J Med Virol*. Jun 1998;55(2):177-83.

11. Cone RW, Swenson PD, Hobson AC, Remington M, Corey L. Herpes simplex virus detection from genital lesions: a comparative study using antigen detection (HerpChek) and culture. *J Clin Microbiol*. Jul 1993;31(7):1774-6.

12. Munday PE, Vuddamalay J, Slomka MJ, Brown DW. Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. *Sex Transm Infect*. Jun 1998;74(3):175-8.

13. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. *Clin Microbiol Rev*. Jan 1999;12(1):1-8.

14. Malkin JE. Herpes simplex virus: who should be tested? *Herpes*. Jul 2002;9(2):31.

15. Copas AJ, Cowan FM, Cunningham AL, Mindel A. An evidence based approach to testing for antibody to herpes simplex virus type 2. *Sex Transm Infect*. Dec 2002;78(6):430-4.

16. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med*. Jan 1 2004;350(1):11-20. doi:10.1056/NEJMoa035144

17. Ramaswamy M, McDonald C, Sabin C, Tenant-Flowers M, Smith M, Geretti AM. The epidemiology of genital infection with herpes simplex virus types 1 and 2 in genitourinary medicine attendees in inner London. *Sex Transm Infect*. Aug 2005;81(4):306-8. doi:10.1136/sti.2004.011643

18. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med*. Aug 21 1997;337(8):509-15. doi:10.1056/nejm199708213370801

19. Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. *Am J Obstet Gynecol*. Aug 2000;183(2):400-6. doi:10.1067/mob.2000.105967

20. Tita AT, Grobman WA, Rouse DJ. Antenatal herpes serologic screening: an appraisal of the evidence. *Obstet Gynecol*. Nov 2006;108(5):1247-53. doi:10.1097/01.AOG.0000236433.29679.9a

21. Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. *Obstet Gynecol*. Feb 2007;109(2 Pt 1):403-9. doi:10.1097/01.AOG.0000251511.27725.5c

22. Bollen LJ, Whitehead SJ, Mock PA, et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? *AIDS*. Jun 19 2008;22(10):1169-76. doi:10.1097/QAD.0b013e3282fec42a

23. Chen KT, Tuomala RE, Chu C, et al. No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. *Am J Obstet Gynecol*. Apr 2008;198(4):399 e1-5. doi:10.1016/j.ajog.2007.10.784

24. Ashley RL. Performance and use of HSV type-specific serology test kits. *Herpes*. Jul 2002;9(2):38-45.

25. Ashley R, Benedetti J, Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. *J Med Virol*. Oct 1985;17(2):153-66.

26. Ashley R. Type-specific antibodies to HSV-1 and-2: review of methodology. *Herpes*. 1998;5:33-38.

27. Smith JS, Bailey RC, Westreich DJ, et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. *Sex Transm Infect*. Apr 2009;85(2):92-6. doi:10.1136/sti.2008.031815

28. Gopal R, Gibbs T, Slomka MJ, et al. A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa. *J Virol Methods*. Jun 2000;87(1-2):71-80.

29. Morrow RA, Friedrich D, Krantz E. Performance of the focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. *J Clin Microbiol*. Nov 2003;41(11):5212-4.

30. van Dyck E, Buve A, Weiss HA, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. *J Clin Microbiol*. Jul 2004;42(7):2961-5. doi:10.1128/jcm.42.7.2961-2965.2004

31. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. *Sex Transm Dis*. Dec 2005;32(12):771-7.

32. Morrow RA, Friedrich D, Meier A, Corey L. Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. *BMC Infect Dis*. 2005;5:84. doi:10.1186/1471-2334-5-84

33. Ashley Morrow R, Krantz E, Friedrich D, Wald A. Clinical correlates of index values in the focus HerpeSelect ELISA for antibodies to herpes simplex virus type 2 (HSV-2). *J Clin Virol*. Jun 2006;36(2):141-5. doi:10.1016/j.jcv.2006.02.006

34. Nascimento MC, Ferreira S, Sabino E, et al. Performance of the HerpeSelect (Focus) and Kalon enzyme-linked immunosorbent assays for detection of antibodies against herpes simplex virus type 2 by use of monoclonal antibody-blocking enzyme immunoassay and clinicovirological reference standards in Brazil. *J Clin Microbiol*. Jul 2007;45(7):2309-11. doi:10.1128/jcm.00144-07

35. LeGoff J, Mayaud P, Gresenguet G, et al. Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. *J Clin Microbiol*. Jun 2008;46(6):1914-8. doi:10.1128/jcm.02332-07

36. Gamiel JL, Tobian AA, Laeyendecker OB, et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. *Clin Vaccine Immunol*. May 2008;15(5):888-90. doi:10.1128/cvi.00453-07

37. van Rooijen MS, Roest W, Hansen G, Kwa D, de Vries HJ. False-negative type-specific glycoprotein G antibody responses in STI clinic patients with recurrent HSV-1 or HSV-2 DNA positive genital herpes, The Netherlands. *Sex Transm Infect*. Jun 2016;92(4):257-60. doi:10.1136/sextrans-2015-052213

38. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. *J Antimicrob Chemother*. Sep 1983;12 Suppl B:79-88.

39. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. *Sex Transm Dis*. Sep 1997;24(8):481-6.

40. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. *Arch Intern Med*. Jan 13 2003;163(1):76-80.

41. Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. *Contact Dermatitis*. Nov 1998;39(5):265-6.

42. Carney O, Ross E, Bunker C, Ikkos G, Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. *Genitourin Med*. Feb 1994;70(1):40-5.

43. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. *Sex Transm Infect*. Dec 1999;75(6):398-402.

44. Green J, Kocsis A. Psychological factors in recurrent genital herpes. *Genitourin Med*. Aug 1997;73(4):253-8.

45. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. *Lancet*. Sep 11 1982;2(8298):571-3.

46. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. *Arch Intern Med*. Aug 12-26 1996;156(15):1729-35.

47. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. *JAMA*. Jul 3 1996;276(1):44-9.

48. Spruance SL, Overall JC, Jr., Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. *N Engl J Med*. Jul 14 1977;297(2):69-75. doi:10.1056/nejm197707142970201

49. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis*. Apr 1 2002;34(7):944-8. doi:10.1086/339325

50. Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. *Sex Health*. Sep 2008;5(3):219-25.

51. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis*. Jan 1 2006;42(1):8-13. doi:10.1086/498521

52. Abudalu M, Tyring S, Koltun W, Bodsworth N, Hamed K. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. *Clin Infect Dis*. Sep 1 2008;47(5):651-8. doi:10.1086/590561

53. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis*. Apr 1 2002;34(7):958-62. doi:10.1086/339326

54. Strand A, Patel R, Wulf HC, Coates KM. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. *Sex Transm Infect*. Dec 2002;78(6):435-9.

55. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. *JAMA*. Jul 8 1988;260(2):201-6.

56. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. *Lancet*. Apr 23 1988;1(8591):926-8.

57. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. *J Am Acad Dermatol*. Aug 2007;57(2):238-46. doi:10.1016/j.jaad.2007.02.008

58. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis*. Mar-Apr 1992;19(2):61-77.

59. Hook EW, 3rd, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. *J Infect Dis*. Feb 1992;165(2):251-5.

60. Mosca JD, Bednarik DP, Raj NB, et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. *Proceedings of the National Academy of Sciences of the United States of America*. Nov 1987;84(21):7408-12.

61. Ostrove JM, Leonard J, Weck KE, Rabson AB, Gendelman HE. Activation of the human immunodeficiency virus by herpes simplex virus type 1. *Journal of virology*. Dec 1987;61(12):3726-32.

62. Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. *J Infect Dis*. Sep 1992;166(3):494-9.

63. Margolis DM, Rabson AB, Straus SE, Ostrove JM. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. *Virology*. Feb 1992;186(2):788-91.

64. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. *J Infect Dis*. May 1994;169(5):956-61.

65. Kreiss J, Carael M, Meheus A. Role of sexually transmitted diseases in transmitting human immunodeficiency virus. *Genitourin Med*. Feb 1988;64(1):1-2.

66. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. *J Infect Dis*. Sep 1989;160(3):380-4.

67. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. *Jama*. Jul 1 1998;280(1):61-6.

68. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. *N Engl J Med*. Feb 22 2007;356(8):790-9. doi:10.1056/NEJMoa062607

69. Todd J, Grosskurth H, Changalucha J, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. *J Infect Dis*. Feb 1 2006;193(3):458-66. doi:10.1086/499313

70. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. *Aids*. Jan 2 2006;20(1):73-83.

71. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. *Sex Transm Dis*. Jan 2000;27(1):21-9.

72. Bagdades EK, Pillay D, Squire SB, O'Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. *Aids*. Nov 1992;6(11):1317-20.

73. Wright PW, Hoesley CJ, Squires KE, Croom-Rivers A, Weiss HL, Gnann JW, Jr. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. *Clin Infect Dis*. Jan 15 2003;36(2):207-11. doi:10.1086/345440

74. Quinnan GV, Jr., Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. *Jama*. Jul 6 1984;252(1):72-7.

75. Maier JA, Bergman A, Ross MG. Acquired immunodeficiency syndrome manifested by chronic primary genital herpes. *Am J Obstet Gynecol*. Oct 1986;155(4):756-8.

76. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. *Drugs*. Dec 2000;60(6):1329-52.

77. Drew WL BW, Erlich KS et al. Chapter 34: Management of herpes virus infection (cytomegalovirus, herpes simplex virus and varicella zoster virus). In: Volberding P, Greene W,Joep L et al. The medical management of AIDS. 9th ed. London: Saunders, 2012, p.433-454.

78. Aoki FY. Management of genital herpes in HIV-infected patients. *Herpes*. Jul 2001;8(2):41-5.

79. Foley E, Patel R. Treatment of genital herpes infections in HIV-infected patients. *Journal of HIV therapy*. Feb 2004;9(1):14-8.

80. Marks GL, Nolan PE, Erlich KS, Ellis MN. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. *Reviews of infectious diseases*. May-Jun 1989;11(3):474-6.

81. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. *Lancet*. Jun 21 2008;371(9630):2109-19. doi:10.1016/s0140-6736(08)60920-4

82. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med*. Feb 4 2010;362(5):427-39. doi:10.1056/NEJMoa0904849

83. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? *Ann Intern Med*. Dec 1 1989;111(11):893-9.

84. Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. *J Infect Dis*. Apr 1990;161(4):711-5.

85. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH, Jr. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. *Ann Intern Med*. Mar 15 1990;112(6):416-22.

86. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. *Clin Infect Dis*. Feb 1 2006;42(3):418-27. doi:10.1086/499356

87. Fox PA, Barton SE, Francis N, et al. Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. *HIV medicine*. Oct 1999;1(1):10-8.

88. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. *J Infect Dis*. Oct 1997;176(4):892-8.

89. CDC - 2015 Sexually Transmitted Diseases Treatment Guidelines - Genital HSV Infections. <http://www.cdc.gov/std/tg2015/herpes.htm> (accessed 2nd September 2016).

90. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. *J Infect Dis*. Oct 1 2003;188(7):1009-16. doi:10.1086/378416

91. Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. *Clin Infect Dis*. Nov 1 2004;39 Suppl 5:S258-66. doi:10.1086/422362

92. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. *AIDS*. Feb 20 2009;23(4):461-9. doi:10.1097/QAD.0b013e32831db217

93. Stranska R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. *J Clin Virol*. Jan 2005;32(1):7-18. doi:10.1016/j.jcv.2004.04.002

94. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. *Antimicrobial agents and chemotherapy*. Nov 1991;35(11):2322-8.

95. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. *Journal of acquired immune deficiency syndromes*. 1992;5 Suppl 1:S29-32.

96. Gnann J, Davis M, Harden E, et al. Resistance T force on H. acyclovir-resistant HSV from HIV-infected individuals. Population surveillance and in vitro characterization of isolates (abstract). New Orleans, USA, 38th Annual International Disease Society of America (IDSA) Meeting, 2000.

97. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. *Jama*. Mar 23-30 1990;263(12):1662-4.

98. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. *Ann Intern Med*. Jun 01 1989;110(11):882-7.

99. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. *Obstet Gynecol*. Dec 2003;102(6):1396-403.

100. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol*. Mar 2003;188(3):836-43.

101. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD, Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. *Infect Dis Obstet Gynecol*. 2002;10(2):71-7. doi:10.1155/s1064744902000054

102. Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. *Br J Obstet Gynaecol*. Mar 1998;105(3):275-80.

103. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD, Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. *Obstet Gynecol*. Jan 1996;87(1):69-73.

104. Braig S, Luton D, Sibony O, et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. *Eur J Obstet Gynecol Reprod Biol*. May 2001;96(1):55-8.

105. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. *Cochrane Database Syst Rev*. 2008;(1):CD004946. doi:10.1002/14651858.CD004946.pub2

106. Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. *Obstet Gynecol*. Jul 2006;108(1):141-7. doi:10.1097/01.aog.0000219749.96274.15

107. James SH, Sheffield JS, Kimberlin DW. Mother-to-Child Transmission of Herpes Simplex Virus. *J Pediatric Infect Dis Soc*. Sep 2014;3 Suppl 1(Suppl 1):S19-23. doi:10.1093/jpids/piu050

108. Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. *J Pediatr*. Jul 2012;161(1):134-8.e1-3. doi:10.1016/j.jpeds.2011.12.053

109. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe F. Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial. *Reprod Health*. Mar 03 2017;14(1):31. doi:10.1186/s12978-017-0292-7

110. Gardella C, Brown ZA, Wald A, et al. Poor correlation between genital lesions and detection of herpes simplex virus in women in labor. *Obstet Gynecol*. Aug 2005;106(2):268-74. doi:10.1097/01.aog.0000171102.07831.74

111. Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. *Obstet Gynecol*. Dec 2005;106(6):1341-8. doi:10.1097/01.AOG.0000185917.90004.7c

112. Poeran J, Wildschut H, Gaytant M, Galama J, Steegers E, van der Meijden W. The incidence of neonatal herpes in The Netherlands. *J Clin Virol*. Aug 2008;42(4):321-5. doi:10.1016/j.jcv.2008.02.004

113. Acyclovir and Valacyclovir in Pregnancy Registry final report. April 1999. <http://pregnancyregistry.gsk.com/acyclovir.html> (accessed 2nd September 2016).

114. Hemelaar SJ, Poeran J, Steegers EA, van der Meijden WI. Neonatal herpes infections in The Netherlands in the period 2006-2011. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. May 2015;28(8):905-9. doi:10.3109/14767058.2014.937691

115. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. *Am J Obstet Gynecol*. Mar 2006;194(3):774-81. doi:10.1016/j.ajog.2005.11.051

116. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. *JAMA*. Aug 25 2010;304(8):859-66. doi:10.1001/jama.2010.1206

117. Acyclovir and Valacyclovir Pregnancy Registries

**Appendices:**

**Search Strategy:**

A literature search was performed using PubMed/MEDLINE, Google, The Cochrane Library and relevant guidelines from January 1981 to August 2023. A MEDLINE/PubMed search was carried out from January 1981 to October August 2023 using the following search terms/Medical Subject Headings (MeSH): “HSV OR herpes”, “genital ulcer OR genital ulcers” and “pregnancy complications: infectious”. The search was limited to humans and the English language. For some specific recommendations, an additional MEDLINE/PubMed search was performed when necessary. A Google search was performed in August 2023with the search term “HSV guideline OR HSV guidelines” and all relevant documents of the first 150 search results were reviewed. A search of The Cochrane Library included the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Cochrane Central Register of Controlled Trials. The following guidelines were reviewed in detail: 2010 European guideline for the management of genital herpes; 2014 BASHH guidance on the management of genital herpes; USA Centers for Disease Control and Prevention 2015 STD Treatment Guidelines; 2023 BASHH/RCOG Joint Guideline on the management of genital herpes in pregnancy; and the 2016 WHO guidelines on the treatment of genital herpes simplex viruses. The members of the guideline development group selected studies relevant to the scope of the guideline. Article titles and abstracts were reviewed and if relevant the full-text article obtained. Priority was given to randomised controlled trial and systematic review evidence and, where possible, recommendations were made and graded on the basis of the best available evidence. In areas where evidence is lacking, recommendations based on consensus opinion within the writing group have been made.

**Grading of Evidence:**

For details of the Tables of levels of evidence and grading of recommendations please see: <http://www.iusti.org/regions/Europe/pdf/2013/Levels_of_Evidence.pdf>

**Statement on declarations of interest**:

None to declare.